| Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis (NCT06747858) | Arcturus Therapeutics, Inc. | 2024-12-12 |
| Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults (NCT06602531) | Arcturus Therapeutics, Inc. | 2024-12-10 |
| A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD (NCT06488313) | Arcturus Therapeutics, Inc. | 2024-11-04 |
| Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults (NCT06279871) | Arcturus Therapeutics, Inc. | 2024-03-27 |
| Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults (NCT06125691) | Arcturus Therapeutics, Inc. | 2024-01-22 |
| Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis. (NCT05712538) | Arcturus Therapeutics, Inc. | 2023-02-15 |
| Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810 (NCT05526066) | Arcturus Therapeutics, Inc. | 2022-10-17 |
| A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults (NCT05037097) | Arcturus Therapeutics, Inc. | 2021-08-30 |
| A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults (NCT04668339) | Arcturus Therapeutics, Inc. | 2021-01-07 |
| Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency (NCT04442347) | Arcturus Therapeutics, Inc. | 2020-11-03 |
| Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects (NCT04480957) | Arcturus Therapeutics, Inc. | 2020-08-04 |
| Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects (NCT04416126) | Arcturus Therapeutics, Inc. | 2020-06-01 |